You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Harnessing the Power of Emerging Therapies in the Management of Patients With Pancreatic Cancer

  • Authors: Lipika Goyal, MD, MPhil; Zev A. Wainberg, MD; Andrew H. Ko, MD, FASCO
  • CME Released: 1/21/2023
  • Valid for credit through: 2/18/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for oncologists, gastroenterologists, and other clinicians involved in the care of patients with pancreatic cancer.

The goal of this activity is for learners to be better able to manage patients with metastatic pancreatic cancer through detailed discussions related to new and current treatment options.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data associated with new therapies used in the first-line setting of metastatic pancreatic cancer
    • Clinical data associated with therapies used in the subsequent-line setting of pancreatic cancer
  • Have greater competence related to
    • Managing the adverse events associated with the therapies used to treat patients with pancreatic cancer
  • Demonstrate greater confidence in their ability to
    • Incorporate new and emerging clinical data into clinical practice to improve the outcomes of patients with pancreatic cancer


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Lipika Goyal, MD, MPhil

    Associate Professor of Medicine
    Stanford School of Medicine
    Director of Gastrointestinal Oncology
    Stanford Cancer Institute
    Palo Alto, California


    Lipika Goyal, MD, MPhil, has the following relevant financial relationships:
    Consultant or advisor for: Alentis Therapeutics AG; AstraZeneca; Black Diamond; Exelixis; Genentech; H3Biomedicine; Incyte Corporation; Kinnate; Merck; QED Therapeutics; Servier, Sirtex Medical Ltd; Surface Oncology; Taiho Oncology Inc; TransTheraBio; Tyra Biosciences

  • Zev A. Wainberg, MD

    Professor of Medicine
    Co-Director, GI Oncology Program
    UCLA Health
    Santa Monica, California


    Zev A. Wainberg, MD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; Arcus; Astellas; AstraZeneca; Bayer; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Genentech; Gilead; Ipsen; Lilly; Merck; Molecular Templates; Novartis; Pfizer; Roche
    Research funding from: Arcus; Bristol Myers Squibb Company; Plexxikon

  • Andrew H. Ko, MD, FASCO

    Professor of Clinical Medicine
    Associate Chief
    Division of Hematology/Oncology
    University of California San Francisco
    San Francisco, California


    Andrew H. Ko, MD, FASCO, has the following relevant financial relationships:
    Consultant or advisor for: Aadi (former); Erytech (former); FibroGen, Inc. (former); FivePrime Therapeutics (former); Ipsen (former); Merus (former); Roche/Genentech; Signatera (former); Turning Point Therapeutics (former); Tyme (former)
    Research funding from: AbGenomics; Apexigen; Astellas; Bristol Myers Squibb Company; Celgene; Crystal Genomics; Leap Therapeutics, Inc.; Merck; Roche/Genentech
    Other: Member of Independent Data Safety Monitoring Committees: Erytech (former); Ipsen (former); Roche/Genentech


  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC 


    Davecia R. Cameron, MS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Harnessing the Power of Emerging Therapies in the Management of Patients With Pancreatic Cancer

Authors: Lipika Goyal, MD, MPhil; Zev A. Wainberg, MD; Andrew H. Ko, MD, FASCOFaculty and Disclosures

CME Released: 1/21/2023

Valid for credit through: 2/18/2023


This certificate page is associated with a Medscape Education event.

Earn Credit

  • Print